我院105例多西紫杉醇不良反应报告分析

Analysis of 105 Docetaxel Related ADR Reports in Our Hospital

目的：了解我院多西紫杉醇不良反应（ADR）发生的特点及其影响因素,为临床合理用药及个体化给药提供参考。方法：通过医院信息系统（HIS）导出我院2014年4月-2015年10月所有使用多西紫杉醇进行抗肿瘤化疗患者的病历,从中调取多西紫杉醇相关ADR报告,通过回顾性分类统计法对ADR报告进行综合分析。结果：417份病例中,有105份多西紫杉醇相关ADR报告,其中50~69岁年龄段的患者有69例次,ADR发生频次最高;女性患者的ADR发生率高于男性患者（29.29%vs.19.66%）;多西紫杉醇相关ADR及骨髓抑制发生率随给药剂量增加均呈升高趋势;乳腺癌的ADR发生频次最高（46.03%）,其次为肺癌和胃癌（分别为37.25%和25.00%）;联合用药方案中,多西紫杉醇＋铂类化疗方案的ADR发生率最高（35.10%）;ADR累及器官/系统以血液系统居首（55.65%）。结论：多西紫杉醇相关ADR的个体差异较大,且受到多种因素的影响,应及早根据患者的个体情况作出评估,减少不良反应的发生,促进临床合理用药。

OBJECTIVE：To investigate the characteristics and influential factors of adverse drug reactions（ADRs）of docetaxel in our hospital,and to provide suggestions for clinical rational drug use and individualized administration. METHODS：Medical records of patients receiving anti-tumor chemotherapy were extracted from hospital information system（HIS）of our hospital during Apr. 2014 and Oct. 2015,and Docetaxel related ADR reports were collected and comprehensively analyzed by retrospective classified statistics. RESULTS：Among 417 cases,105 cases of docetaxel related ADR were reported. There were 69 patients aged 50-69 with highest ADR frequency. The ADR incidence of female patients was higher than that of male patients（29.29% vs. 19.66%）.The incidence of docetaxel related ADR and arrest of bone marrow increased as the increase of drug dosage;the incidence of breast cancer ADR was the highest（46.03%）,followed by lung cancer（37.25%） and gastric cancer（25.00%）. The incidence of docetaxel ＋ platinum chemotherapy plan ADR was the highest（35.10%）. Main organs/system involved in ADR was hematological system（55.65%）. CONCLUSIONS：The individual difference of docetaxal related ADR are great and affected by several factors.Individual physical condition of patients should be taken into consideration as early as possible,which can reduce the incidence of ADR and promote clinical rational drug use.